Drugs in development for the treatment of osteoporosis: Tibolone
Gorai, I.
Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 3): 552-571
2002
ISSN/ISBN: 0047-1852 PMID: 11979954 Document Number: 550345
Document emailed within 1 workday
Related Documents
Taga, M. 2002: Drugs in development for the treatment of osteoporosis:Raloxifene Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 3): 572-580Ciesielska-Kopacz, N.; Kos-Kudła, B.; Pluskiewicz, W. 1998: The influence of thyroid diseases and their treatment on the development of osteoporosis Przeglad Lekarski 55(5): 271-273
Radowicki, S.; Arsoba, J.; Dubrawski, W. 1988: Tibolone (Livial) in the treatment of disorders of the postmenopausal period (preliminary report) Ginekologia Polska 59(11): 705-708
Soen, S. 2007: First choice drug for treatment of osteoporosis and the strategic points for choice of drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 9): 325-328
Martiradonna, A.; Terlizzi, N.; D'Amore, M.; Pallante, R.; Carrozzo, M. 1981: Experimental osteoporosis caused by calcium deficiency in rats: treatment with calcium salts and synthetic anabolic drugs La Clinica Terapeutica 97(6): 587-604
Traianos, A.; Vavilis, D.; Makedos, A.; Karkanaki, A.; Ravanos, K.; Prapas, N.; Tarlatzis, B.C. 2013: Effect of short-term tibolone treatment on risk markers for cardiovascular disease in healthy postmenopausal women: a randomized controlled study Clinical and Experimental Obstetrics and Gynecology 40(4): 542-545
Asakura, H.; Sugimura, K. 1999: Present states of development in new drugs and treatment of inflammatory bowel disease Nihon Rinsho. Japanese Journal of Clinical Medicine 57(11): 2490-2495
2006: Osteoporosis drugs and jaw problems. Weighing your risks Mayo Clinic Health Letter 24(12): 6
Halse, J.; Falch, J.; Haug, E.; Jorde, R.; Nesheim, B.I.; Nordal, K.P.; Skjaeraasen, J.; Aanderud, S. 1995: Osteoporosis drugs prescribed on blue forms! Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(24): 3050-3051
De, D.P. 1994: Current thoughts about the mechanism of drug addiction and the possibility of development of new drugs in its treatment Journal of the Indian Medical Association 92(7): 239-240
Reginster, J.Y. 1996: Prevention of postmenopausal osteoporosis: estrogens and nonhormonal drugs Revue Medicale de Liege 51(10): 649-653
Ammann, P.; Rizzoli, R.; Bonjour, J.P. 1999: Animal models for the preclinical testing of drugs against osteoporosis Revue du Rhumatisme 66(11): 532-533
Aksaranugraha, S. 2011: Observation: application and advantages of BMK in osteoporosis by monitoring the dose of antiresorptive drugs with CTx Journal of the Medical Association of Thailand 94(Suppl 5): S63-S70
Beerhorst, K.; Huvers, F.C.; Renier, W.O. 2005: Severe early onset osteopenia and osteoporosis caused by antiepileptic drugs Netherlands Journal of Medicine 63(6): 222-226
Minakuchi, M.; Tanaka, E.; Inoue, T.; Sakuramoto, M.; Maeda, Y.; Maniwa, K.; Taguchi, Y. 2005: An adult case of cervico-mediastinal lymph nodes tuberculosis followed by the development of pulmonary lesions during the treatment with antituberculous drugs Kekkaku: 80(1): 19-23
Blanco Sampascual, S.; de Las Heras Niño, B.; Cabezudo Gil, P.; Ruiz Eguiluz, P.; Orive Cura, V. 2002: Tibolone-induced hepatotoxicity Gastroenterologia y Hepatologia 25(4): 274
Roshan, J.; Ganesh, A. 2002: Tibolone, blood pressure and obesity National Medical Journal of India 15(3): 180
Serati, M.; Uccella, S.; Bolis, P. 2008: Tibolone in older postmenopausal women New England Journal of Medicine 359(20): 2173; Author Reply 2173
Woodward, A.H.; Jowsey, J. 1974: Estrogens and development of immobilization osteoporosis in rats Surgical Forum 25: 480-481
Rygnestad, T. 1992: Development of physostigmine from a poisonous plant to an antidote. one of the most important drugs in the development of modern medicine? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 112(10): 1300-1303